Novavax Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $49.35. The key difference: Novavax Inc is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| NVAX | QCLN | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | Sector/Thematic |
52-Week High | $11.19 | $68.47 |
52-Week Low | $6.22 | $37.69 |
Enterprise Value | $1.26B | — |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
QCLN trades at $50.57, up 2.31% today, with a bullish technical signal overall despite bearish moving averages. The ETF is positioned to benefit from global renewable energy acceleration driven by geopolitical tensions and rising data center power demand. Recent news highlights its sensitivity to U.S. political outcomes and federal clean energy policy, with historical outperformance ahead of midterm elections.
The outlook is supported by structural tailwinds in clean energy adoption, but risks include regulatory uncertainty and permit delays under current U.S. administration. Investment appeal hinges on policy continuity and execution of global renewable projects, with volatility expected around political developments.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →